A Phase II Study of Targeted Brachytherapy for Low Risk Prostate Cancer Patients
PRIMARY OBJECTIVES:
I. To determine long term 5 year prostate specific cancer (PSA) biochemical control using
the Phoenix definition of PSA nadir + 2 of targeted hemi-gland brachytherapy.
SECONDARY OBJECTIVES:
I. To assess acute and late toxicity outcomes following targeted brachytherapy according to
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
II. To determine changes from baseline in health-related quality of life indicators using
the validated Expanded Prostate Cancer Index Composite (EPIC) questionnaire, International
Index of Erectile Function (IIEF) questionnaire, and International Prostate Symptom Score
(IPSS) questionnaire.
III. To assess the potential value of multiparametric magnetic resonance imaging, including
dynamic contrast enhancement perfusion imaging and diffusion tensor neurovascular
tactographic imaging in predicting the development of equivocal disease (ED) following
radiation treatment.
OUTLINE:
Patients undergo 3 fractions of image-guided high-dose rate (HDR) brachytherapy over 2 days.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then annually thereafter.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Biochemical PSA control using the Phoenix definition of PSA nadir + 2
5 years
No
Mitchell Kamrava
Principal Investigator
Jonsson Comprehensive Cancer Center
United States: Institutional Review Board
11-003235
NCT01859689
March 2012
Name | Location |
---|---|
Jonsson Comprehensive Cancer Center | Los Angeles, California 90095 |